FHTX Stock Extends Sell-Off After Eli Lilly Collaboration Ends
Foghorn Therapeutics (FHTX) shares dropped over 28% on Friday, extending a previous day's 18% slump, following the termination of its cancer-drug collaboration with Eli Lilly (LLY). The biotech firm announced it would cease development of FHD-909.